相关实验视频
Updated: Jun 9, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.5K
血小板中的PROTACs:新兴的抗血栓策略和未来的前景
Justin S Trory1, Jordan Vautrinot, Carl J May
1School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
Current opinion in hematology
|October 24, 2024
概括
蛋白质溶解向的嵌合体 (PROTACs) 可以降解无核血小板中的蛋白质,提供新的抗血栓治疗方法. 这种方法显示出研究血小板功能和治疗血栓形成的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白质分解向化马体 (PROTACs) 是癌症等疾病的新兴治疗方法.
- PROTACs提供了一种选择性降解标蛋白的新方法.
研究的目的:
- 探索 PROTACs 在无核血小板中的应用.
- 评估PROTACs在血小板中的抗血栓潜力.
主要方法:
- 人类血小板的蛋白质和生物化学分析.
- 基于神经 (CRBN) 配体的PROTACs的应用,向氨酸激酶 (Btk, Fak).
- 在体外评估蛋白质降解和血栓形成.
主要成果:
- 人类血小板具有乌比基蛋白质体系统和CRBN,使它们对PROTACs敏感.
- 基于CRBN的PROTACs有效降解了人体血小板中的Btk等标蛋白.
- 降低Btk的调节受损了体外血栓的形成,但没有影响血液静止.
结论:
- 血小板容易受到PROTACs的向蛋白质降解的影响.
- 血小板中有限的蛋白质合成确保了持续的目标下调.
- PROTACs是血小板研究的宝贵工具,并且对抗血栓策略具有治疗前景.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
478
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
478
Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Venous Thrombosis III: Interprofessional Care
2
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
2
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Formation of the Platelet Plug
4.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154

